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Protection against Mycobacterium tuberculosis is based on cell-mediated immunity, most importantly involving CD4+ and CD8+
T-cellsubsets.TheaimofthisstudywastoevaluateCD4+ andCD8+ T-cellproﬁlesandCD19+ andCD3−CD(16+56)+ populations
in patients with pulmonary tuberculosis. CD4+ and CD8+ T cells, B-lymphocytes, and natural killer (NK) cells were evaluated in
75 active (APTB) and 25 inactive (IPTB) pulmonary tuberculosis cases and 20 healthy subjects (HCs). The results were compared
at diﬀerent stages of antituberculosis treatment in the APTB patients and also according to X-ray ﬁndings in the newly diagnosed
APTB patients. The percentages of CD4+ T cells were signiﬁcantly lower (P<. 01) and those of CD3−CD(16 + 56)+ cells were
signiﬁcantlyhigher(P<. 01)inAPTBpatientsthaninHCs.CD8+ Tcellsweresigniﬁcantlydecreased(P<. 05),andCD3−CD(16+
56)+ cellsweresigniﬁcantlyincreased(P<. 01),inIPTBpatientscomparedtoHCs.ThepercentagesofCD4+,CD8 +,CD3 −CD19+,
and CD3−CD(16+56)+ cells showed no diﬀerences at diﬀerent times of the antituberculosis regimen, and diﬀerent stages of newly
diagnosed APTB patients. APTB patients have a reduced percentage of circulating CD4+ T cells and an increased percentage of
NK cells compared with healthy individuals. These cells could play important roles in the immune response to M tuberculosis
infection.
Copyright © 2006 Figen Deveci et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
The host immune response to Mycobacterium tuberculosis,
especially cell-mediated immunity, is particularly important
in preventing clinically evident disease following infection.
CD4+ T cells have an essential role in this response but
are supported by other T-cell subsets such as CD8+ [18].
Antigen-presentingcellsexpressthecostimulatorymolecules
necessaryforactivatingTcells.How Tcellshelpthemtoper-
form this task remains poorly understood. Primarily, CD4+
T cells are involved in amplifying immune responses by se-
creting various cytokines, but some CD4+ T cells also serve
as cytotoxic eﬀector cells capable of lysing target cells directly
[1].
Although decreased CD4+ T cell counts and changes in
CD8+ T cell counts are pivotal immune abnormalities in
HIV patients, TB may be a cause of non-HIV associated
CD4+ lymphopenia [2]. Despite the pivotal importance of
CD4+ and CD8+ lymphocytes in antimicrobial immunity,
very few researchers have studied changes in the peripheral
blood counts of these cells in TB cases, and these few have
obtained diﬀerent results.
The aim of this study was to compare the baseline and
posttreatment levels of the CD4+ and CD8+ T-cell subsets,
and the CD3−CD19+ B-lymphocytes, and CD3−CD(16 +
56)+ NK cell counts, with the radiological extent of the dis-
ease in APTB patients and also in IPTB patients.
MATERIALS AND METHODS
Patientsandstudydesign
This study was performed on randomly selected 75 APTB
patients (age: mean ± SD = 35.76 ± 15.8; 39 women, 36
men) who had been admitted to the Firat Medical Center
and Elazig Tuberculosis Dispensary. APTBs were diagnosed
on the basis of presence of recent clinical symptoms of tu-
berculosis, a positive sputum smear test for acid-fast bacilli
conﬁrmed by a positive culture of M tuberculosis and charac-
teristics chest radiograph. No extrapulmonary involvement2 Mediators of Inﬂammation
was detected in the patients. The exclusion criteria were HIV
positivity, diabetes mellitus, pregnancy, and immunological
or autoimmune diseases. Also, APTB patients were divided
into three treatment groups as follows [1].
Accordingtoantituberculosistreatment(ATT)
Group 1. 25 newly diagnosed APTB patients. None of the
cases had a priori history of TB or any relevant clinical or
radiological ﬁndings.
Group 2. 25 patients who had undergone 2-month quadru-
plet antituberculosis treatment (Rifampin, Pyrazinamide,
Isoniazid, and Streptomycin or Ethambutol).
Group 3. 25 patients who had been treated with antitubercu-
losis drugs for 6 months.
In addition, Group 1 patients indicated above were di-
vided into three stages according to the extent and type of
X-ray ﬁndings as follows [3].
AccordingtotheX-rayﬁndings
Stage 1 (mild cases, n = 11). Involving a single lobe without
visible cavities.
Stage 2 (moderate cases, n = 8). Unilateral involvement of
two or more lobes with cavities, if present, reaching a total
diameter no more than 4cm.
Stage 3 (advanced cases, n = 6). Bilateral disease with mas-
sive involvement and multiple cavities.
Twenty ﬁve inactive (ages 40.23 ± 20.5, 9 women, 16
men) pulmonary TB (IPTB) cases who had been registered
andtreatedintheElazigTuberculosisDispensarywereexam-
ined, and 20 healthy volunteer subjects (ages 38.20 ± 17.6, 9
women,11men)wereincludedasacontrolgroup(HC).The
IPTBpatientshadhadapreviousepisodeofTB,withpositive
culturesdocumentedatthetimeofdiagnosis.Therewereab-
normal but stable radiographic ﬁndings, and no changes had
been observed in previous six months. At least three sputum
cultures for M tuberculosis had been negative in all these pa-
tients [4]. The healthy subjects had no abnormal X-ray ﬁnd-
ings or history of TB and no other underlying disease, and
they were not currently taking any medication.
Smears were pretreated with N-acetylcysteine and
4% sodium hydroxide. The samples were cultured in
Lowenstein-Jensen medium and were examined weekly un-
t i lg r o w t hw a sd e t e c t e d .C u l t u r e sw e r er e p o r t e da sn e g a t i v e
if there was no growth after 8 weeks. Cultures with visi-
ble growth were processed for biochemical identiﬁcation of
species by standard methods.
Tuberculinwasidentiﬁedinthepatientsbythecutaneous
Mantoux test: 5 IU PPD (BB-NCIPD Ltd, Sophia, Bulgaria)
was injected intradermally into the volar surface of the fore-
arm. Speciﬁcally trained nurses read the PPD reactivity, 72
hours after application, by measuring the transverse axis of
induration (not erythema) with a ﬂexible ruler. The exact
number of millimeters was recorded. A transverse indura-
tion of ≥ 10mm was considered a positive response. All
APTB and IPTB patients were positive for the PPD skin test.
Healthy subjects had been vaccinated with BCG as part of
the obligatory Turkey National Vaccination Program and all
were tuberculin positive.
Before the study, informed consent was obtained from all
participants.
Flowcytometricanalysisofperipheralblood
Peripheral venous blood samples (5mL) were collected into
tubes with EDTA from all the individuals diagnosed with tu-
berculosis and controls and were subjected to ﬂow cytom-
etry within 2 hours. Absolute lymphocyte counts (ALCs)
were analyzed using a Coulter Max-M (Beckman Coulter,
Fullerton, Calif, USA). Lymphocyte subsets analyses were
performed using a Coulter EPICS XL-MCL (Beckman Coul-
ter, Fullerton, Calif, USA). The results were counted on
the same equipment using an Expo-32 analysis programmer
and Immunotech (Margeille, France). Monoclonal antibod-
ies against the following markers were deployed according
to the manufacturer’s instructions: CD14/CD45, CD3/CD4,
CD3/CD8,CD3/CD19,andCD3/CD(16+56),andanisotype
control. A total of 10000 cells were counted, and the results
were interpreted using isotypic controls after performing the
voltage tunings required. Each lymphocyte subpopulation
countwasexpressedasapercentageofthetotalofCD3+ lym-
phocytes. Criteria of quality included a greater than 95% to-
tal lymphocyte frequency in the analysis gate and a homoge-
nous CD45+ population.
Statisticalanalysis
Results are expressed as arithmetic means ± standard devia-
tions.StatisticalanalysiswasperformedusingKruskal-Wallis
test for multiple-group comparisons; Mann-Whitney U test
was performed to test any observed diﬀerences for signiﬁ-
cance. Also, correlation analysis was performed with Spear-
man’s test. All statistical analysis were performed by using
SPSS version 12.00. Statistical signiﬁcance was interfered at
a P value < 0.05.
RESULTS
There were no statistically signiﬁcant diﬀerences in age or
gender among the subject groups. The mean PPD response
was statistically higher in APTB (15.35 ± 2.78, range 11–
24mm) and IPTB (13.92 ± 2.25, range 10–17mm) patients
t h a ni nH C( 1 1 .80 ± 1.64, range 10–16mm), (p = 0.000
for APTB and p = 0.007 for IPTB compared with HCs).
There were no correlations between PPD and the T lym-
phocyte subset counts or the percentages of CD3−CD19+ or
CD3−CD(16 + 56)+ in APTB or IPTB patients or controls
(P>. 05 for all groups).
Thepercentages(mean%±SD)ofserumtotalCD3+ lym-
phocytes (TL%), ALC, the percentages of T-cell subsets, B
cells, and NK cells are given in Table 1.Figen Deveci et al 3
Table 1: The mean percentages of total lymphocytes, B-lymphocytes, T-lymphocyte subsets, CD3−CD(16 + 56)+, and absolute lymphocyte
counts in the study groups.
APTB (n = 75) IPTB (n = 25) HC (n = 20) Statistics
Total lymphocytes (%) 25.70 ±10.20a 37.79 ±7.23b 30.13 ± 7.64 P<. 001a, P<. 01b
ALC (cell/mm3) 1407.6 ±206.5a 2136.1 ±488.1b 1528.1 ± 243.1 P<. 001a, P<. 001b
CD3+CD4+(%) 36.52 ±8.66b 39.28 ±8.17 43.36 ± 6.01 P<. 01b
CD3+CD8+(%) 26.30 ±8.40 22.13 ±5.75b 27.16 ± 7.01 P<. 05b
CD3−CD19+(%) 12.51 ±6.37 14.13 ±4.10 11.86 ± 3.26 NS
CD3−CD(16+56)+(%) 15.86 ±7.76b 17.36 ±7.48b 11.03 ± 6.71 P<. 01b
CD4+/CD8
+ ratio 1.57 ±0.75 1.88 ±0.64 1.69 ±0.46 NS
ALC: absolute lymphocyte counts, acompared to IPTB, bcompared to HC
,.
T h ep e r c e n t a g e so ft o t a lC D 3 + lymphocytes and ALC
were lower signiﬁcantly in APTB than IPTB patients (P<
.001 for both) and these values signiﬁcantly higher in IPTB
patients than in HC (P<. 01 for TL%, P<0.001 for ALC).
APTB patients had lower CD3+CD4+ (P<0.01) and higher
CD3−CD(16 + 56)+ (P<0.01) levels than HC but similar
CD3+CD8+ subset proportions. There were no statistically
signiﬁcant diﬀerences among the groups in the percentages
of CD3−CD19+. IPTB patients had higher CD3−CD(16 +
56)+ (P<. 01) and lower CD3+CD8+ levels (P<. 05) than
HCs.
Group 1 APTB patients had lower TL% (p = 0.012) and
ALC (p = 0.017) than HCs. Groups 1 and 2 APTB patients
had lower CD3+CD4+ (p = 0.006 for Group 1, p = 0.000 for
Group 2)andhigherproportionsofCD3−CD(16+56)+ (p =
0.022 for Group 1, p = 0.004 for Group 2) than HCs. How-
ever,therewerenostatisticallysigniﬁcantdiﬀerencesinTL%,
ALC, percentages of CD3+CD4+,o rC D 3 −CD(16 + 56)+
among the three APTB groups, although there was a trend
toward a higher level of TL%, ALC, and levels of CD3+CD4+
and lower levels of CD3−CD(16 + 56)+ in Groups 2 and
3. No statistically signiﬁcant diﬀerences in these parameters
were observed between APTB Group 3 and HCs (P>. 05).
The percentages of CD3+CD8+ and the CD3−CD19+ ratios
in APTB Groups 1, 2,a n d3 were similar to those in HCs
(Figure 1).
APTB Groups 1, 2,a n d3 had fewer TL% (p = 0.000 for
Group 1, p = 0.001 for Group 2, p = 0.003 for Group 3)
and ALC (p = 0.000 for all) than ITBP. ITBP had more TL%
(p = 0.009), ALC (p = 0.000), and CD3−CD(16+56)+ (p =
0.007) than HCs, and ITBP had lower CD3+CD8+ than HCs
(p = 0.043) and Group 3 ATBP (p = 0.008) (Figure 1).
When the lymphocyte counts were compared to the X-
ray ﬁndings, there were no signiﬁcant diﬀerences among
Stages 1 to 3 of Group 1 APTB patients in percentages of
CD3+CD4+,C D 3 +CD8+,C D 3 −CD19+,o rC D 3 −CD(16 +
56)+ (P>. 05).
DISCUSSION
The major ﬁnding of this study was a decrease in CD3+CD4+
and increase in CD3−CD(16+56)+ in APTB, and in Group 1
of APTB, compared to HC. There were no signiﬁcant diﬀer-
ences in the percentages of CD3+CD4+ and CD3−CD(16 +
56)+ between HC and patients who had received six months
ofantituberculosistherapy.Thepercentagesoftotallympho-
cytes were lower in APTB patients than in IPTB patients or
HCs. Similarly, the study by Montes Santiago et al [5] indi-
cated a progressive lymphopenia, especially in patients with
more extensive pulmonary TB. Another study suggested that
the severity of TB disease is associated with greater depres-
sion of the total lymphocyte and CD4 cell counts [6].
T-lymphocyte subsets, particularly CD4+, play a crucial
role in immunity against mycobacterium infections [7, 8]. In
general, very few researchers have studied the changes in pe-
ripheral blood counts of T-cell subsets in TB cases, and even
these few have obtained diﬀerent results. In some studies, the
percentages of CD4 cells were decreased while the percent-
ages of CD8 cells were unchanged compared with controls
[9–12]. However, another studies showed, especially in ad-
vanced or disseminated TB, that CD4+ T cells are reduced
while CD8+ T cells are increased [6, 13]. In contrast, there
are reports of unchanged proportions of CD4 cells in the pe-
ripheral blood of TB patients compared with controls. Shi-
jubo et al [14] found only CD8+ T cells to be signiﬁcantly
decreased; the other T-cell subsets were normal. A study per-
formed in our country showed no signiﬁcant diﬀerences in
CD4+ or CD8+ T cells between nonresistant TB patients and
healthy controls [15]. In our study, the APTB patients had
a signiﬁcantly lower percentage of CD4+ T cells in the pe-
ripheral blood than HC. This ﬁnding accord with the re-
sults obtained from previous studies that suggest a decreased
CD4+ lymphocyte percentage in the peripheral blood of TB
patients[2,9,16].Inaddition,inthepresentstudy,nosignif-
icant diﬀerences were observed in the percentages of CD4+ T
cell according to severity (extent and type of X-ray ﬁndings)
of TB disease. This could be interpreted as indicating that
CD4+ cells are critical at all stages of M tuberculosis infection.
We found that the percentages of CD3+CD8+ in APTB
patients were similar to those in HCs the same as previous
studies. [15, 17] .T h er o l eo fC D 8 + T cells in human immune
responses to M tuberculosis, and their relationship to other
T-cell subsets activated by M tuberculosis, is not well deﬁned.
For humans, it is not known at what stages of M tuberculosis
infection CD8+ Tc e l l sa r em o s tc r i t i c a l[ 18].4 Mediators of Inﬂammation
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Figure 1: Percentages of total lymphocytes, CD3+CD4+,C D 3 −CD(16+56)+ and CD3+CD8+ lymphocytes in the study groups. (a) Group 1
APTB patients versus HC: p = 0.012; Group 1 APTB patients versus IPTB patients: p = 0.000; IPTB patients versus HC: p = 0.009, Group 2
APTB patients versus IPTB patients: p = 0.001; Group 3 APTB patients versus IPTB patients: p = 0.003, (b) Group 1 APTB patients versus
HC: p = 0.006, Group 2 APTB patients versus HCs: p = 0.000, (c) Group 1 APTB patients versus HC: p = 0.022; IPTB patients versus HC:
p = 0.007, Group 2 APTB patients versus HCs: p = 0.004, (d) IPTB patients versus HC: p = 0.043; Group 3 APTB patients versus IPTB
patients: p = 0.008.
In the present study, the percentages of CD3−CD19+
were similar in APTB patients and HCs. There are only a few
studiesexplainingtheroleofB-lymphocytesinTB,andthese
have given diﬀerent results. The role of B cells during Mt u -
berculosis infection is not clear. Previous studies suggest lit-
tle contribution from B cells to the control or exacerbation
of M tuberculosis infections in mice during chronic phases
of infection [19, 20]. Other studies have shown no diﬀer-
ence in B-lymphocyte counts between pulmonary TB and
control groups [5, 14]. In contrast to studies dealing with
pulmonary TB patients and tuberculin skin-test-positive
controls, Coraminas et al found a decrease in B cells. They
interpreted this as indicating that B-cell counts are the best
discriminating factor for infection, and that B-lymphocytes
have an important role in immunity against tuberculosis
[21].
The role of NK cells in the host defense against Mt u -
berculosis remains unexplored. Some studies suggest that NK
cellshavearoleindefenseagainstmycobacterialinfectiones-
pecially in early resistance [22–25], and both the percentage
of NK cells and the NK activity were increased in APTB pa-
tients [26, 27]. In our study, CD3−CD(16 + 56)+ was foundFigen Deveci et al 5
to be increased in both APTB and IPTB patients compared
to HCs. Thus, NK cells may have an important role in im-
munity against TB.
What are the eﬀects of antituberculosis therapy on the
decreased CD4+ and increased CD3−CD(16 + 56)+ cell
counts in these patients? Although there was a trend toward
higher levels of CD4+ and lower levels of CD3−CD(16+56)+
in APTB Groups 2 and 3, we found no signiﬁcant diﬀer-
ences among the APTB groups. When patients who had
been treated for 6 months were compared with HCs, we
observed no statistically signiﬁcant diﬀerences in these cell
populations. Previous studies have shown that the decreased
CD4+ T-cell counts returned to normal levels after therapy
[6, 13, 15, 28]. In patients with pulmonary TB, decreased
CD4 and increased CD8 cell counts and near-normal levels
of CD4/CD8 have been reported after successful chemother-
apy [15]. Other studies showed no changes in the number of
N Kc e l l s ,b u tT Bp a t i e n t sh a dad e c r e a s e dN Ka c t i v i t y ,w h i c h
increased after treatment [25, 29].
We found that APTB and IPTB patients diﬀered only
in TL% and ALC. Morikawa et al [30] demonstrated that
APTB patients had higher NK activity than IPTB pa-
tients. A signiﬁcantly greater percentage of BAL CD8+ cells
have been reported in APTB compared with IPTB patients
[31].
In the present study, we found no diﬀerences in the NK
cells between patients treated for 6 months and HC, but the
NK cell counts were higher in IPTB than HCs. Although
no diﬀerences were observed between APTB and IPTB in
CD8+Tcells,IPTBhadlowerlevelsofCD8+TcellsthanHCs.
Further studies will be needed to explain why lower levels of
CD8+T cells were detected in IPTB.
How does the radiological extent of the disease inﬂuence
theimmuneparameters?Wefoundnodiﬀerencesamongthe
diﬀerentstagesofAPTBinanyparameter.Otherstudieshave
also shown that lymphocyte subset numbers bear no relation
to the radiographic scores [16, 17, 32]. Qin [27] found that
NK activity increased as the TB lesion progressed, as judged
from X-ray pictures; but the T-lymphocyte subsets were un-
related to the severity or extent of the lesion as judged radio-
logically.
CONCLUSIONS
Low percentages of CD4+ T cells and high percentages of NK
cells in APTB, and high NK cells and low CD8+ Tc e l l si n
IPTB, show that CD4+ and NK cells have an important role
in the control of active disease and NK, and CD8+ Tc e l l s
may have a role in the inactive disease. The low percentages
of CD4+ T cells and high percentages of NK cells in APTB
patients would be potentially reversible by antituberculosis
treatment. In addition measuring of these parameters may
be useful for monitoring the clinical eﬀect of antitubercu-
losis treatment. However, in this study, we studied diﬀerent
patients and diﬀerent time periods of treatment. Thus, it can
be more useful to evaluate the lymphocytes subsets on the
same patients longitudinally.
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